Mustang Bio is a clinical-stage biopharmaceutical company focused on cell and gene therapies for hematologic cancers, solid tumors and rare genetic diseases. Co.'s pipeline is focused in three main areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. In partnership with St. Jude Children's Research Hospital, Co.'s gene therapy program is being conducted under a license to develop a treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The MBIO stock yearly return is shown above.
The yearly return on the MBIO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MBIO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|